What is Trevi Therapeutics, Inc. (TRVI)?

Trevi Therapeutics, Inc. (TRVI) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of TRVI?

The current price of TRVI is $13.56. Prices are updated in real time on Stocks360.

What is TRVI's price-to-earnings (PE) ratio?

TRVI's trailing twelve-month PE ratio is -40.14, based on current price and earnings per share data available on Stocks360.

What is TRVI's market capitalization?

TRVI's market capitalization is $1,931,972,404.00, placing it in the small-cap tier.

Trevi Therapeutics, Inc. (TRVI)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$13.56

Market Cap

$1.93B

PE (TTM)

-40.14

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.98

Day Range

$13.44 – $13.91

52-wk Range

$9.82 – $20.22

Avg Volume

N/A

Volume

1.73M

Trevi Therapeutics, Inc. (TRVI) is a publicly traded company in the Healthcare sector. Latest price: $13.56. Market cap $1.93B. Trailing PE -40.14. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 10 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-31 · $11.66 2026-10-30 · $13.56 (+16.30%)

Earnings

Most Recent

Aug 6, 2026

EPS $-0.11 vs est. $-0.11

Missed by $0.00

Next Earnings

Nov 12, 2026

EPS estimate $-0.13

Proprietary Signals

Signal snapshot temporarily unavailable.

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-40.14×
P/S (TTM)	0.00×
P/B	6.60×
P/FCF (TTM)	-49.05×
EV / EBITDA	-36.80×
EV / Sales	0.00×
Earnings Yield	-2.41%
Free Cash Flow Yield	-2.04%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$1.88B
Net Income (TTM)	-$46.50M
Free Cash Flow (TTM)	-$52.87M
Net Debt	-$53.70M
Working Capital	$316.97M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-23.59%
Return on Invested Capital	-18.46%